Company

GSK

London-headquartered pharmaceutical company; Jemperli (dostarlimab-gxly), its PD-1 inhibitor, was first approved in 2021 for mismatch repair-deficient endometrial cancer and now carries five U.S. oncology indications.

gsk.com

3 stories

Regulatory News has published 3 stories about GSK between 25 August 2026 and 21 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 21 October 2026.

This page is generated from Regulatory News’ editorial coverage of GSK. It is not an advertisement.

Products in our coverage

Jemperli®dostarlimab-gxly

Our coverage

3 stories, newest first.

A smiling physician in a dark suit, standing in for GSK's leadership announcing the Jemperli rectal cancer approval

For Physicians FDA Approves First Immunotherapy for Rectal Cancer Oct 21, 202610 min read Read the story

A patient's bandaged hand resting on an infusion-chair armrest, an IV line in place, standing in for Jemperli's intravenous dosing

Drugs & Biologics FDA Approves GSK's Jemperli for Rectal Cancer Oct 21, 20266 min read Read the story

Three scientists in a sunlit lab examine a bottle and a bowl of solution while adjusting laboratory equipment

Drugs & Biologics EU Approves GSK's Twice-Yearly Asthma Drug Exdensur Aug 25, 20265 min read Read the story

All companies